approves

If you live with type 2 diabetes (T2D) and find the frequency of multiple daily injections (MDI) dauntinghere’s a bit of good news: Eli Lilly announced the Food and Drug …

The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for adults with type 2 diabetes (T2D). This …

September 24, 2026 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email …

Health 8 sources·Updated Sep 24, 2026 The U.S. Food and Drug Administration on Thursday, Sept. 24, 2026, approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults …

FDA approved of Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin indicated along with diet and exercise to control high blood sugar in adults with type 2 diabetes. With FDA’s …

September 17, 2026 1 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email …

The US Food and Drug Administration (FDA) has approved an updated label for insulin human (Afrezza) inhalation powder, which provides guidance for starting dosages when switching from multiple daily injections …

GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones that broaden …

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), significantly improving access to diabetes treatment. Glucagon-like peptide-1 (GLP-1) receptor agonists are designed to …

Underlying technology A brief history of CGM CGM is a wearable technology that allows users to track their blood sugar levels in real time. Historically, people with type 1 or …